Healthcare Industry News: Parkinson's Disease
News Release - August 16, 2011
NeuroLogica Corporation Receives CE Mark for Its Portable, High-Resolution SPECT Camera, the inSPira HD(TM)DANVERS, Mass.--(Healthcare Sales & Marketing Network)-- NeuroLogica Corporation (http://www.NeuroLogica.com) announced that it received CE Mark approval for its inSPira HD™. As a result, the portable, high-resolution Single Photon Emission Computed Tomography (SPECT) camera will now be made available within the European Union and other select markets.
Designed primarily for brain imaging, the battery-powered inSPira HD™ can provide high-quality SPECT images in any venue, including epilepsy clinics, ICUs and private practice neurological imaging centers. The high-resolution camera is capable of imaging any radioisotope energies between 80-200 keV for clinical applications such as epilepsy, Parkinson's Disease, neuropsychology, stroke and brain perfusion as well as Alzheimer's disease and dementia.
"Features such as high spatial resolution, convenience, portability and versatility set the inSPira HD™ apart from other brain SPECT imaging systems currently on the American and European markets," said Dr. Colin Timothy McDonald, NeuroLogica's chief medical officer. "The technologies in traditional systems haven't really changed since the 1960s so they continue to suffer from poor spatial and contrast resolution, in short, 'fuzzy imaging.'" The inSPira HD™ presents a new method of SPECT detection, acquisition and reconstruction, which is designed to approach a spatial resolution of 3mm, rivaling that of PET imaging.
"Images obtained with the inSPira HD™ SPECT camera provide a much higher spatial resolution than with any other SPECT camera on the market," said Dr. Jean-Paul Soucy, director of the PET unit at the Montreal Neurological Institute. "Since inSPira HD™ has reconstructed spatial resolution to 3mm and true attenuation correction, it will give physicians more detailed clinical information of brain activity by allowing them to better evaluate cerebral blood flow distribution patterns at a resolution higher than anything ever achieved in that field before."
Now that it has successfully completed the European Union conformity assessment, NeuroLogica is inviting attendees of the World Molecular Imaging Congress Annual Meeting in San Diego to conduct their own evaluations of the inSPira HD™ at Booth #410 September 7-10, 2011.
NeuroLogica Corporation (http://www.NeuroLogica.com) specializes in the design and manufacture of medical imaging equipment that is easy to use and brings the power of imaging to the patient wherever they may be. The company's mission is to bring high-quality medical imaging to all people regardless of where they live. NeuroLogica's BodyTom™ CT, CereTom® CT, and inSPira HD™ SPECT are FDA registered and the quality system is certified to ISO 13485:2003 and ISO 9001:2008 with Canadian Medical Device Amendments. NeuroLogica's CereTom® CT is CE marked (European Conformity) for distribution in the European Union and European Economic Area.
Source: NeuroLogica Corp
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.